Matthew Murphy

Oct 30, 2024 | streetwisereports.com | Matthew Murphy

Close Important Disclosures: Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.

Oct 21, 2024 | jdsupra.com | Matthew Murphy

In a trade secret misappropriation action, a complainant is required to prove the amount of its damages with reasonable certainty and that this amount has been caused by the misappropriation. Therefore, the trade secret owner should be prepared to explain how its claimed or awarded damages are sufficiently apportioned to the trade secrets alleged or found to have been misappropriated. Easy to say in principle, harder to execute in real life.

Aug 27, 2024 | msn.com | Matthew Murphy

Microsoft Cares About Your PrivacyMicrosoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.

Apr 24, 2024 | jdsupra.com | Matthew Murphy

Today, the U.S. Federal Trade Commission (“FTC”) adopted a final rule (3-2) banning new non-compete agreements for both senior executives and non-senior executives. Companies may continue to enforce existing non-compete agreements entered into with “senior executives.” However, preexisting non-compete agreements for all other workers will become unenforceable (recission not required) and companies will be obligated to provide adequate notice to all such workers.

Apr 23, 2024 | jdsupra.com | Thomas Hedemann |Chad Landmon |Matthew Murphy

Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law. Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries.